Last Updated : September 8, 2016
Details
FilesProject Line:
Health Technology Review
Project Number:
HT0015-000
Date NOC Issued:
The number of drugs available for sedation of patients in the intensive care unit (ICU) is limited, with both benzodiazepines and propofol being commonly used.
Dexmedetomidine is a selective alpha-2 adrenergic agonist with sedative properties; it produces a pattern of sedation different from other drugs.
The choice of sedative drugs in the ICU setting is important, as the drug selected can affect patient outcomes, making their use an important formulary policy decision for acute-care hospitals. Decisions will be made from a quality of care and a budgetary perspective, as substantial cost differences exist between these drugs.
This project aims at assessing the cost-effectiveness of dexmedetomidine for the sedation of patients in the ICU. Findings will inform formulary decisions regarding the use of dexmedetomidine in Canadian regional health authorities and hospitals.
Files
Dexmedetomidine for Sedation in the Critical Care Setting
Technology Review
In Brief
PUBLISHED: June 2017
Dexmedetomidine for Sedation in the Critical Care Setting: An Economic Assessment
Technology Review
Economic Assessment
PUBLISHED: March 2017
Files
Last Updated : September 8, 2016